11 September 2018
Visiongain has launched a new pharma report: In-Vitro Diagnostics World Market 2018-2028: Point of Care, Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Molecular Diagnostics, Flow Cytometry, Infectious Diseases, Diabetes, Cardiology, Autoimmune Diseases, Renal Diseases, Pharmacogenomics, HIV/AIDS, Reagent & Kits, Instruments, Data Management Software & Services, Hospitals, Laboratories, Home Care Testing, Research Institutes, Blood Glucose Testing, Infectious Disease Testing, Rapid Coagulation Testing, Cholesterol Testing, Pregnancy Testing, Basic Metabolic Panel, Electrolyte Panel, Liver Profile, Lipid Profile, Thyroid Function Test, ELISA, Immuno-PCR, Rapid Test, Western Blot, Enzyme linked Immunospot Assay
In vitro diagnostic (IVD) tests are medical assays performed on bodily fluids or tissues, as a diagnostic tool for a range of clinical disorders. The information obtained from such tests may act as a key factor in the decision making of a patient’s particular treatment plan. Examples of tests currently performed today include measuring the concentrations of various chemical and biochemical components, counting cells, measuring physical properties of the sample, microscopic examination of cells and other structures or preparing biological cultures. The generally positive outlook for the IVD industry has led to a large amount of merger and acquisition activity over previous years. These market trends are set to continue as the larger industry leaders look to consolidate power in an industry which is set to be worth $78.4bn by 2020.
The lead analyst of the report commented "Strengths in the IVD market primarily results from patient demographics. The rise in the global aging population will bear witness to an increasing incidence of age-related diseases, such as cardiovascular disease and cancer. This in turn has fuelled demand for advanced diagnostic testing equipment, capable of providing accurate clinical diagnoses, which allows for earlier medical intervention.
In addition, technological innovations in this field have introduced increasingly miniaturised and automated devices into the marketplace, which has given rise to a new range of condition-specific tests. Furthermore, continued research and development in IVD has allowed the discovery of new biomarkers, which has expanded the clinical application of IVD testing."
Leading companies featured in the report include Abbott Diagnostics, Agilent Technologies, Becton, Dickinson and Company (BD), BioMerieux, Bio-Rad, Danaher Corporation, DiaSorin Diagnostics s.p.a, Roche Diagnostics, Siemens Diagnostics, Sysmex Corporation
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.
14 May 2019
Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.
09 May 2019
The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.
07 May 2019
The cancer treating drugs market will continue to grow over the next ten years.